1. Home
  2. AKRO vs WKC Comparison

AKRO vs WKC Comparison

Compare AKRO & WKC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • WKC
  • Stock Information
  • Founded
  • AKRO 2017
  • WKC 1984
  • Country
  • AKRO United States
  • WKC United States
  • Employees
  • AKRO N/A
  • WKC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • WKC Oil Refining/Marketing
  • Sector
  • AKRO Health Care
  • WKC Energy
  • Exchange
  • AKRO Nasdaq
  • WKC Nasdaq
  • Market Cap
  • AKRO 2.4B
  • WKC 1.6B
  • IPO Year
  • AKRO 2019
  • WKC N/A
  • Fundamental
  • Price
  • AKRO $33.04
  • WKC $28.34
  • Analyst Decision
  • AKRO Strong Buy
  • WKC Hold
  • Analyst Count
  • AKRO 7
  • WKC 5
  • Target Price
  • AKRO $43.20
  • WKC $30.20
  • AVG Volume (30 Days)
  • AKRO 571.1K
  • WKC 943.8K
  • Earning Date
  • AKRO 11-08-2024
  • WKC 10-24-2024
  • Dividend Yield
  • AKRO N/A
  • WKC 2.39%
  • EPS Growth
  • AKRO N/A
  • WKC 28.11
  • EPS
  • AKRO N/A
  • WKC 2.24
  • Revenue
  • AKRO N/A
  • WKC $44,410,500,000.00
  • Revenue This Year
  • AKRO N/A
  • WKC N/A
  • Revenue Next Year
  • AKRO N/A
  • WKC $3.53
  • P/E Ratio
  • AKRO N/A
  • WKC $12.68
  • Revenue Growth
  • AKRO N/A
  • WKC N/A
  • 52 Week Low
  • AKRO $13.47
  • WKC $19.81
  • 52 Week High
  • AKRO $37.00
  • WKC $31.71
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 59.08
  • WKC 48.30
  • Support Level
  • AKRO $31.12
  • WKC $27.90
  • Resistance Level
  • AKRO $35.88
  • WKC $29.12
  • Average True Range (ATR)
  • AKRO 1.66
  • WKC 0.87
  • MACD
  • AKRO 0.27
  • WKC 0.06
  • Stochastic Oscillator
  • AKRO 62.12
  • WKC 43.12

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About WKC World Kinect Corporation

World Kinect Corp is a energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers . It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. Company operate in three reportable segments consisting of aviation, land, and marine. Company earn majority of revenue from Aviation segment.

Share on Social Networks: